139 related articles for article (PubMed ID: 27734748)
1. Cost analysis of cetuximab (Erbitux) plus radiotherapy (ERT) versus concomitant cisplatin plus radiotherapy (CRT) within an NHS oncology unit (single institution): a pilot study.
Caroline B; Sundus Y; Dawn D; Carol G; Susan M
Br J Radiol; 2016 Dec; 89(1068):20160105. PubMed ID: 27734748
[TBL] [Abstract][Full Text] [Related]
2. Phase II/III Randomized Controlled Trial of Concomitant Hyperfractionated Radiotherapy plus Cetuximab (Anti-EGFR Antibody) or Chemotherapy in Locally Advanced Head and Neck Cancer.
Al-Saleh K; El-Sherify M; Safwat R; Elbasmy A; Shete J; Hussein A; Nazeeh M; Bedair A
Gulf J Oncolog; 2019 May; 1(30):6-12. PubMed ID: 31242976
[TBL] [Abstract][Full Text] [Related]
3. Concurrent cisplatin or cetuximab with radiotherapy for HPV-positive oropharyngeal cancer: Medical resource use, costs, and quality-adjusted survival from the De-ESCALaTE HPV trial.
Jones DA; Mistry P; Dalby M; Fulton-Lieuw T; Kong AH; Dunn J; Mehanna HM; Gray AM
Eur J Cancer; 2020 Jan; 124():178-185. PubMed ID: 31794928
[TBL] [Abstract][Full Text] [Related]
4. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.
Gillison ML; Trotti AM; Harris J; Eisbruch A; Harari PM; Adelstein DJ; Jordan RCK; Zhao W; Sturgis EM; Burtness B; Ridge JA; Ringash J; Galvin J; Yao M; Koyfman SA; Blakaj DM; Razaq MA; Colevas AD; Beitler JJ; Jones CU; Dunlap NE; Seaward SA; Spencer S; Galloway TJ; Phan J; Dignam JJ; Le QT
Lancet; 2019 Jan; 393(10166):40-50. PubMed ID: 30449625
[TBL] [Abstract][Full Text] [Related]
5. Weekly cetuximab concurrent with IMRT aggravated radiation-induced oral mucositis in locally advanced nasopharyngeal carcinoma: Results of a randomized phase II study.
Xu T; Liu Y; Dou S; Li F; Guan X; Zhu G
Oral Oncol; 2015 Sep; 51(9):875-9. PubMed ID: 26163437
[TBL] [Abstract][Full Text] [Related]
6. Cetuximab and Radiotherapy Versus Cisplatin and Radiotherapy for Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial.
Magrini SM; Buglione M; Corvò R; Pirtoli L; Paiar F; Ponticelli P; Petrucci A; Bacigalupo A; Crociani M; Lastrucci L; Vecchio S; Bonomo P; Pasinetti N; Triggiani L; Cavagnini R; Costa L; Tonoli S; Maddalo M; Grisanti S
J Clin Oncol; 2016 Feb; 34(5):427-35. PubMed ID: 26644536
[TBL] [Abstract][Full Text] [Related]
7. Indirect comparison of the efficacy of cetuximab and cisplatin in squamous cell carcinoma of the head and neck.
Levy AR; Johnston KM; Sambrook J; Donato B; Penrod JR; Corral M; Chasen M
Curr Med Res Opin; 2011 Dec; 27(12):2253-9. PubMed ID: 22017232
[TBL] [Abstract][Full Text] [Related]
8. Real-world cost-effectiveness of cetuximab in locally advanced squamous cell carcinoma of the head and neck.
van der Linden N; van Gils CW; Pescott CP; Buter J; Vergeer MR; Groot CA
Eur Arch Otorhinolaryngol; 2015 Aug; 272(8):2007-16. PubMed ID: 24943191
[TBL] [Abstract][Full Text] [Related]
9. Assessing Care Value for Older Patients Receiving Radiotherapy With or Without Cisplatin or Cetuximab for Locoregionally Advanced Head and Neck Cancer.
Saraswathula A; Chen MM; Colevas AD; Divi V
JAMA Otolaryngol Head Neck Surg; 2019 Dec; 145(12):1160-1167. PubMed ID: 31621810
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Cetuximab plus Radiotherapy in Cisplatin-Unfit Elderly Patients with Advanced Squamous Cell Head and Neck Carcinoma: A Retrospective Study.
Addeo R; Caraglia M; Vincenzi B; Luce A; Montella L; Mastella A; Mazzone S; Ricciardiello F; Carraturo M; Del Prete S; Sperlongano P
Chemotherapy; 2019; 64(1):48-56. PubMed ID: 31242489
[TBL] [Abstract][Full Text] [Related]
11. Subgroup Analysis According to Human Papillomavirus Status and Tumor Site of a Randomized Phase II Trial Comparing Cetuximab and Cisplatin Combined With Radiation Therapy for Locally Advanced Head and Neck Cancer.
Buglione M; Maddalo M; Corvò R; Pirtoli L; Paiar F; Lastrucci L; Stefanacci M; Belgioia L; Crociani M; Vecchio S; Bonomo P; Bertocci S; Borghetti P; Pasinetti N; Triggiani L; Costa L; Tonoli S; Grisanti S; Magrini SM
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):462-472. PubMed ID: 27986347
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of concurrent bio-chemoradiotherapy using docetaxel, cisplatin, and cetuximab for locally advanced head and neck squamous cell carcinoma.
Nishimura G; Taguchi T; Takahashi M; Shiono O; Komatsu M; Sano D; Yabuki K; Arai Y; Takahashi H; Hata M; Oridate N
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1315-9. PubMed ID: 27154176
[TBL] [Abstract][Full Text] [Related]
13. Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: satellite--a phase II study from the Swedish Lung Cancer Study Group.
Hallqvist A; Wagenius G; Rylander H; Brodin O; Holmberg E; Lödén B; Ewers SB; Bergström S; Wichardt-Johansson G; Nilsson K; Ekberg L; Sederholm C; Nyman J
Lung Cancer; 2011 Feb; 71(2):166-72. PubMed ID: 20541833
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial.
Martins RG; Parvathaneni U; Bauman JE; Sharma AK; Raez LE; Papagikos MA; Yunus F; Kurland BF; Eaton KD; Liao JJ; Mendez E; Futran N; Wang DX; Chai X; Wallace SG; Austin M; Schmidt R; Hayes DN
J Clin Oncol; 2013 Apr; 31(11):1415-21. PubMed ID: 23460709
[TBL] [Abstract][Full Text] [Related]
15. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm.
Pfister DG; Su YB; Kraus DH; Wolden SL; Lis E; Aliff TB; Zahalsky AJ; Lake S; Needle MN; Shaha AR; Shah JP; Zelefsky MJ
J Clin Oncol; 2006 Mar; 24(7):1072-8. PubMed ID: 16505426
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness of Cetuximab for Advanced Esophageal Squamous Cell Carcinoma.
Janmaat VT; Bruno MJ; Polinder S; Lorenzen S; Lordick F; Peppelenbosch MP; Spaander MC
PLoS One; 2016; 11(4):e0153943. PubMed ID: 27100871
[TBL] [Abstract][Full Text] [Related]
17. The toxicity and efficacy of concomitant chemoradiotherapy in patients aged 70 years and older with oropharyngeal carcinoma in the intensity-modulated radiotherapy era.
Zumsteg ZS; Lok BH; Ho AS; Drill E; Zhang Z; Riaz N; Shiao SL; Ma J; McBride SM; Tsai CJ; Baxi SS; Sherman EJ; Lee NY
Cancer; 2017 Apr; 123(8):1345-1353. PubMed ID: 27984656
[TBL] [Abstract][Full Text] [Related]
18. Survival of patients with head and neck cancer treated with definitive radiotherapy and concurrent cisplatin or concurrent cetuximab: A Surveillance, Epidemiology, and End Results-Medicare analysis.
Xiang M; Holsinger FC; Colevas AD; Chen MM; Le QT; Beadle BM
Cancer; 2018 Dec; 124(23):4486-4494. PubMed ID: 30332498
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes and prognostic factors in cisplatin versus cetuximab chemoradiation for locally advanced p16 positive oropharyngeal carcinoma.
Barney CL; Walston S; Zamora P; Healy EH; Nolan N; Diavolitsis VM; Neki A; Rupert R; Savvides P; Agrawal A; Old M; Ozer E; Carrau R; Kang S; Rocco J; Teknos T; Grecula JC; Wobb J; Mitchell D; Blakaj D; Bhatt AD
Oral Oncol; 2018 Apr; 79():9-14. PubMed ID: 29598954
[TBL] [Abstract][Full Text] [Related]
20. Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with cisplatin concurrent chemoradiotherapy for nonmetastatic Stage IV head-and-neck squamous cell carcinomas.
Prestwich RJ; Öksüz DÇ; Dyker K; Coyle C; Şen M
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e237-43. PubMed ID: 21620580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
